Boston Scientific Stock Price Outlook: Is a 40% Surge Possible?

Boston Scientific (BSX) stock has fallen 30% YTD due to various issues, including a 9% drop on March 30. Despite beating Q4 2025 estimates, Q1 2026 guidance came in below expectations. The EP segment missed in Q4, and the FDA flagged battery issues in the Accolade pacemaker line. However, the company's fundamentals remain strong, with revenue growth at 16.6% annually over three years, compared to 4.9% for Medtronic (MDT) and 0.7% for Abbott (ABT). BSX trades at 18.1x forward earnings, below its three-year historical average of 26.5x, implying a price of approximately $87, or 40% upside from current levels.